Alembic Pharmaceuticals Receives USFDA Approval for Levothyroxine Sodium Tablets

Alembic Pharmaceuticals Limited has secured final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP.

What Just Happened

The approval covers a comprehensive range of dosages: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. These tablets are therapeutically equivalent to the reference listed drug, Synthroid Tablets by AbbVie, Inc.

Why This Matters

This approval signifies a significant addition to Alembic's U.S. generic drug portfolio, targeting a substantial market. Levothyroxine Sodium Tablets are crucial for hormone replacement therapy in hypothyroidism and as an adjunct treatment for certain thyroid cancers.

The Backstory

Alembic Pharmaceuticals has been steadily building its U.S. regulatory approvals. The company now holds a cumulative total of 239 ANDA approvals from the USFDA, comprising 220 final and 19 tentative approvals.

Market Opportunity

The U.S. market for Levothyroxine Sodium Tablets USP was valued at approximately US$ 1,869 million for the twelve months ending March 2026, according to IQVIA data. This substantial market size presents a significant revenue potential for the company.

Risks to Watch

While the approval is positive, generic drug markets are highly competitive, which can lead to pricing pressures. Success will depend on Alembic's ability to effectively market and distribute the product to capture market share.

Peer Comparison

Alembic Pharmaceuticals competes in the generics market with numerous other Indian pharmaceutical companies that also have a strong focus on U.S. FDA approvals. Companies like Sun Pharma, Dr. Reddy's Laboratories, and Cipla also have extensive ANDA portfolios.